Can the radiation dose be safely reduced in the treatment of nk/T cell lymphoma?

References

• Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-cell lymphoma project. Blood. 2009;113(17):3931–3937. doi:10.1182/blood-2008-10-185256
   PubMed Web of Science ®Google Scholar
• Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429–434. doi:10.1309/AJCP7YLTQPUSDQ5C
   PubMed Web of Science ®Google Scholar
• Li YX, Liu QF, Wang WH, et al. Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy. Cancer. 2011;117(22):5203–5211. doi:10.1002/cncr.26167
   PubMed Web of Science ®Google Scholar
• Wang L, Wang ZH, Chen XQ, et al. First-line combi­nation of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119(2):348–355. doi:10.1002/cncr.27752
   PubMed Web of Science ®Google Scholar
• Qi F, Wang WH, He XH, et al. Phase 2 Study of first-line intensity modulated radiation Therapy followed by gemcitabine, dexamethasone, and cisplatin for high-risk, early stage extranodal nasal-type NK/T-cell lymphoma: the GREEN Study. Int J Radiat Oncol Biol Phys. 2018;102(1):61–70. doi:10.1016/j.ijrobp.2018.05.046
   PubMed Web of Science ®Google Scholar
• Yahalom J, Illidge T, Specht L et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2015;92(1):11–31. doi:10.1016/j.ijrobp.2015.01.009
   PubMed Web of Science ®Google Scholar
• Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24(1):181–189. doi:10.1200/JCO.2005.03.2573
   PubMed Web of Science ®Google Scholar
• Li YX, Wang H, Jin J, et al. Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1809–1815. doi:10.1016/j.ijrobp.2010.10.040
   PubMed Web of Science ®Google Scholar
• Deng XW, Wu JX, Wu T, et al. Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: a multicenter study from the China lymphoma collaborative group (CLCG). Radiother Oncol. 2018;129(1):3–9. doi:10.1016/j.radonc.2018.04.026
   PubMed Web of Science ®Google Scholar
• Qi SN, Li YX, Specht L, et al. Modern radiation therapy for extranodal nasal-type nK/T-cell Lymphoma: risk-adapted therapy, target volume, and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2021;110(4):1064–1081. doi:10.1016/j.ijrobp.2021.02.011
   PubMed Web of Science ®Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity of the radiation therapy oncology group (RTOG) and the European Organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–1346. doi:10.1016/0360-3016(95)00060-C
   PubMed Web of Science ®Google Scholar
• Yang Y, Cao JZ, Lan SM, et al. Association of improved locoregional control with prolonged Survival in early-stage extranodal nasal-type natural killer/T-cell lymphoma. JAMA Oncol. 2017;3(1):83–91. doi:10.1001/jamaoncol.2016.5094
   PubMed Web of Science ®Google Scholar
• Vargo JA, Patel A, Glaser SM, et al. The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States. Cancer. 2017;123(16):3176–3185. doi:10.1002/cncr.30697
   PubMed Web of Science ®Google Scholar
• Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18(1):54–63. doi:10.1200/JCO.2000.18.1.54
   PubMed Web of Science ®Google Scholar
• Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006;106(3):609–615. doi:10.1002/cncr.21656
   PubMed Web of Science ®Google Scholar
• Koom WS, Chung EJ, Yang WI, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004;59(4):1127–1137. doi:10.1016/j.ijrobp.2003.12.006
   PubMed Web of Science ®Google Scholar
• Wang L, Bi XW, Xia ZJ, et al. Radiation dose reduction for patients with extranodal NK/T-cell lymphoma with complete response after initial induction chemotherapy. Onco Targets Ther. 2016;9:5875–5881. doi:10.2147/OTT.S116591
   PubMed Web of Science ®Google Scholar
• Song Y, Li J, Wang S, et al. The promising outcome with simultaneous integrated boost intensity modulated radiotherapy in confined nasal extranodal NK/T-cell lymphoma. Leuk Lymphoma. 2021;62(12):2907–2914. doi:10.1080/10428194.2021.1948035
   PubMed Web of Science ®Google Scholar
• Qi S, Yahalom J, Hsu M, et al. Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. Leuk Lymphoma. 2016;57(11):2575–2583. doi:10.1080/10428194.2016.1180689
   PubMed Web of Science ®Google Scholar
• Wang H, Li YX, Wang WH, et al. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(3):1115–1121. doi:10.1016/j.ijrobp.2011.02.039
   PubMed Web of Science ®Google Scholar